Exciting News! US FDA Inspection Concludes With Zero Observations

We are pleased to inform you that our recent FDA inspection at our Shanghai site concluded on August 8th with exceptionally positive results.

We have completed a Pre-Approval Inspection (PAI) at our Shanghai site. The inspection of the drug substance facility was carried out from June 11 to June 14, 2024, and concluded with zero 483 observations.

About ChemExpress

ChemExpress is committed to offering our partners a high quality, highly efficient end-to-end service platform that focuses on small molecules and new modalities, including ADC payloads & linkers, ADC conjugation, peptides, oligonucleotides, protacs, etc.

Our comprehensive CRO & CDMO platform provides full lifecycle services from R&D through commercialization, and supply of reference compounds, building blocks, RSMs, intermediates, APIs and drug products.

Welcome to visit us via our website: https://www.chemexpress.com/

To know more about us via our company video: https://www.youtube.com/watch?v=nEydgaZwXlA

Any questions, please contact us at info@chemexpress.com